Biomarkers in Brain Disease
30 Jan '09, Said Business School
The development of reliable biomarkers for brain disorders would dramatically accelerate research on the etiology, pathophysiology, disease progression and therapeutic development of many diseases including Alzheimer’s, Parkinson’s and multiple sclerosis.
International experts in neuroscience and related diseases attended this meeting to discuss the latest advances in biomarker technologies and the logistical, regulatory and funding challenges related to clinical trials for brain disorder biomarkers.
The meeting was co-hosted by the NYAS and GMEC and the proceedings can be found here
